Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 5/20 | 0.58 |
| ▸ | IKBKB | O14920 | 12/20 | 0.58 |
| ▸ | CHUK | O15111 | 11/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518918 | 0.85 | AURKA (0.50) | NEK1IKBKBCHUKROCK1AURKA | |
| SCHEMBL6522272 | 0.82 | AURKA (0.56) | IKBKBCHUKAURKAAURKB | |
| SCHEMBL6522008 | 0.80 | AURKA (0.49) | NEK1IKBKBCHUKAURKAAURKB | |
| SCHEMBL12846620 | 0.79 | AURKA (0.63) | IKBKBCHUKROCK1AURKAAURKB | |
| SCHEMBL13680303 | 0.77 | AURKA (0.67) | AURKAAURKB | |
| SCHEMBL12846362 | 0.77 | AURKA (0.57) | AURKAAURKB | |
| SCHEMBL6531867 | 0.77 | AURKA (0.57) | AURKAAURKB | |
| SCHEMBL6519395 | 0.77 | AURKA (0.65) | AURKAAURKB | |
| SCHEMBL27946467 | 0.75 | AURKA (0.56) | IKBKBCHUKROCK1AURKAAURKB | |
| SCHEMBL6518123 | 0.74 | GAA (0.50) | IKBKBCHUKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| CN-101952287-B | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2013-11-27 | — | — | CN | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | NEK1 164/4885IKBKB 234/4885CHUK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.